Collegium Pharmaceutical (NASDAQ:COLL) Stock Jumps 4.1% – Time to Buy?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was up 4.1% on Wednesday. The company traded as high as $22.14 and last traded at $22.4170. 32,509 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 571,868 shares. The stock had previously closed at $21.53.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on COLL shares. Leerink Partners initiated coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price for the company. Piper Sandler reiterated a “neutral” rating and issued a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Zacks Research cut shares of Collegium Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Oppenheimer initiated coverage on Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 price target for the company. Finally, Barclays decreased their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, August 19th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $48.71.

Collegium Pharmaceutical Price Performance

The stock has a 50-day moving average of $24.58 and a two-hundred day moving average of $31.03. The firm has a market cap of $729.02 million, a price-to-earnings ratio of 18.08, a price-to-earnings-growth ratio of 0.71 and a beta of 0.73. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.68 earnings per share. On average, analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.18 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in COLL. BlackRock Inc. bought a new position in shares of Collegium Pharmaceutical in the second quarter worth about $196,972,000. Jupiter Topco LLC acquired a new position in shares of Collegium Pharmaceutical during the second quarter valued at about $77,743,000. Janus Henderson Group PLC increased its stake in Collegium Pharmaceutical by 26.0% during the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after acquiring an additional 377,073 shares during the period. Dimensional Fund Advisors LP raised its holdings in Collegium Pharmaceutical by 0.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 833,192 shares of the specialty pharmaceutical company’s stock valued at $27,551,000 after acquiring an additional 2,712 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Collegium Pharmaceutical by 29.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 703,528 shares of the specialty pharmaceutical company’s stock worth $23,266,000 after purchasing an additional 159,755 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.